2024年11月7日,专注于免疫介导型皮肤病治疗的生物技术公司Arcutis Biotherapeutics Inc.(ARQT)在盘中出现大涨,股价一度上涨6.83%,引发市场关注。
分析人士指出,推动ARQT股价上涨的主因或与公司主打产品ZORYVE roflumilast乳膏取得关键进展有关。根据公司此前发布的消息,该产品在治疗斑块状银屑病的3期临床试验中表现出良好的疗效和安全性。作为一种创新型外用疗法,ZORYVE乳膏有望填补银屑病等免疫介导性皮肤病领域长期存在的临床需求空白。
另一方面,ARQT最新公布的财报数据也呈现向好态势。上一季度该公司实现营业收入3086万美元,较上年同期大幅增长;虽然目前仍处于亏损状态,但随着主打产品上市销售,有望在未来实现盈利。加之多数机构分析师维持"买入"评级,也为ARQT股价上涨增添了动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.